Lakefront Biotherapeutics American Depositary Shares
LKFT
90 hedge funds and large institutions have $1.03B invested in Lakefront Biotherapeutics American Depositary Shares in 2025 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 28 increasing their positions, 33 reducing their positions, and 17 closing their positions.
3,920% more call options, than puts
Call options by funds: $804K | Put options by funds: $20K
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0.01% less ownership
Funds ownership: 47.65% → 47.64% (-0.01%)
6% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 17
2% less funds holding
Funds holding: 92 → 90 (-2)
5% less capital invested
Capital invested by funds: $1.09B → $1.03B (-$57.1M)
15% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$6.34M |
| 2 |
Millennium Management
New York
|
+$6.02M |
| 3 |
BlackRock
New York
|
+$2.4M |
| 4 |
D.E. Shaw & Co
New York
|
+$2.38M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$2.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$7.43M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
-$2.45M |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$2.42M |
| 4 |
Goldman Sachs
New York
|
-$1.78M |
| 5 |
Primecap Management
Pasadena,
California
|
-$1.75M |
LKFT Hedge Fund Activity: Q4 2025 in Review
90 of the 8,280 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q4 2025, worth a combined $1.03B — down 5.3% from $1.09B a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of LKFT and 16 opened new positions — a net loss of 1 holder — while 33 trimmed existing stakes and 28 added.
The largest buyer was UBS Group, adding an estimated $6.34M. The largest seller was Tang Capital Management, cutting an estimated $7.43M.
- 90 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q4 2025, down from 92 in Q3 2025.
- Funds reported $1.03B of Lakefront Biotherapeutics American Depositary Shares stock for Q4 2025, down 5.3% quarter-over-quarter.
- 16 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q4 2025 and 17 closed out, a net change of -1 holder.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q4 2025 was UBS Group, an estimated $6.34M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q4 2025 was Tang Capital Management, an estimated $7.43M sold.
Based on aggregated 13F filings for Q4 2025.